Go Pro
→ Bernie is gunning for your money (From Porter & Company) (Ad)tc pixel
NASDAQ:RZLT

Rezolute Q4 2024 Earnings Report

Rezolute logo
$4.68 -0.01 (-0.21%)
As of 04:00 PM Eastern
ProfileEarnings HistoryForecast

Rezolute EPS Results

Actual EPS
-$0.44
Consensus EPS
-$0.30
Beat/Miss
Missed by -$0.14
One Year Ago EPS
N/A

Rezolute Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Rezolute Announcement Details

Quarter
Q4 2024
Date
9/19/2024
Time
After Market Closes
Conference Call Date
Thursday, September 19, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

Rezolute's Q4 2026 earnings is estimated for Wednesday, September 16, 2026, based on past reporting schedules, with a conference call scheduled on Monday, September 14, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Rezolute's Q4 2024 Press ReleasePress Release
(8-K)
Rezolute's Q4 2024 Annual reportAnnual report
(10-K)

Rezolute Earnings Headlines

Analysts Offer Insights on Healthcare Companies: Rezolute (RZLT) and Boston Scientific (BSX)
July 30, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/RZLT/pressreleases/3559521/analysts-offer-insights-on-healthcare-companies-rezolute-rzlt-and-boston-scientific-bsx/
Rezolute, Inc. (NASDAQ:RZLT) Receives Average Recommendation of "Moderate Buy" from Analysts
July 30, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30930456
The cat is out the bag
Almost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered separation packages to 8,500 workers, and Oracle is reportedly eliminating up to 30,000 positions. Goldman Sachs estimates 12,400 Americans are being financially displaced every single day. Analyst Porter Stansberry says the real driver runs deeper than AI - and two Nobel Prize winners have issued the same warning. He calls it the Final Displacement, and he's releasing a full investigation with specific companies to buy and sell before the next wave hits.tc pixel
August 10 at 1:00 AM  |  Porter & Company (Ad)
Rezolute to Participate in the BTIG Virtual Biotechnology Conference
July 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/21/3330330/0/en/rezolute-to-participate-in-the-btig-virtual-biotechnology-conference.html
Rezolute Inc.
June 29, 2026  |  marketwatch.comhttps://www.marketwatch.com/investing/stock/rzlt/financials/cash-flow
FDA Grants Orphan Drug Designation to Rezolute's Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
June 25, 2026  |  stockhouse.comhttps://stockhouse.com/news/press-releases/2024/12/03/fda-grants-orphan-drug-designation-to-rezolute-s-ersodetug-rz358-for-the
See More Rezolute Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Rezolute? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rezolute and other key companies, straight to your email.

About Rezolute

Rezolute (NASDAQ:RZLT), a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

View Rezolute Profile
Earnings Tools